The results shown here confirm our previous finding in CRC (Fiore et al., 2019), highlighting that even in GBM, IPA and its synthetic analog N6-BA upregulate the expression and, indirectly, the activity of the oncosuppressor FBXW7 emerged in the last years as an appealing therapeutic target in different cancers. Here, FBXW7 is linked to cancer.